A first-in-human study of ANN-002 in treatment of hereditary angioedema

Trial Profile

A first-in-human study of ANN-002 in treatment of hereditary angioedema

Planning
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs ANN 002 (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 08 Nov 2017 According to an Adverum Biotechnologies media release, the Company also plans to file an IND application with the FDA in the second half of 2018.
    • 13 May 2016 According to an Avalanche Biotechnologies media release, this trial is expected to initiate in 2017.
    • 13 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top